News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
475,732 Results
Type
Article (32607)
Company Profile (306)
Press Release (442819)
Multimedia
Podcasts (70)
Webinars (9)
Section
Business (136497)
Career Advice (2588)
Deals (25124)
Drug Delivery (96)
Drug Development (66198)
Employer Resources (159)
FDA (10720)
Job Trends (11292)
News (241433)
Policy (23526)
Tag
Academia (2091)
Accelerated approval (4)
Adcomms (18)
Allergies (73)
Alliances (35052)
ALS (80)
Alzheimer's disease (1206)
Antibody-drug conjugate (ADC) (119)
Approvals (10732)
Artificial intelligence (208)
Autoimmune disease (21)
Automation (12)
Bankruptcy (239)
Best Places to Work (9245)
BIOSECURE Act (18)
Biosimilars (75)
Biotechnology (253)
Bladder cancer (69)
Brain cancer (24)
Breast cancer (244)
Cancer (1963)
Cardiovascular disease (161)
Career advice (2175)
Career pathing (33)
CAR-T (143)
Cell therapy (399)
Cervical cancer (17)
Clinical research (53611)
Collaboration (716)
Compensation (310)
Complete response letters (17)
COVID-19 (2272)
CRISPR (45)
C-suite (208)
Cystic fibrosis (97)
Data (1981)
Decentralized trials (2)
Denatured (17)
Depression (45)
Diabetes (221)
Diagnostics (4207)
Digital health (15)
Diversity (4)
Diversity, equity & inclusion (33)
Drug discovery (112)
Drug pricing (106)
Drug shortages (18)
Duchenne muscular dystrophy (93)
Earnings (53229)
Editorial (44)
Employer branding (21)
Employer resources (138)
Events (73722)
Executive appointments (614)
FDA (11756)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (658)
Gene editing (109)
Generative AI (19)
Gene therapy (305)
GLP-1 (621)
Government (3950)
Grass and pollen (2)
Guidances (55)
Healthcare (14511)
Huntington's disease (22)
IgA nephropathy (28)
Immunology and inflammation (112)
Indications (27)
Infectious disease (2390)
Inflammatory bowel disease (130)
Inflation Reduction Act (11)
Influenza (40)
Intellectual property (87)
Interviews (518)
IPO (12960)
IRA (47)
Job creations (2428)
Job search strategy (1788)
Kidney cancer (9)
Labor market (30)
Layoffs (402)
Leadership (21)
Legal (4762)
Liver cancer (53)
Lung cancer (273)
Lymphoma (132)
Machine learning (6)
Management (57)
Manufacturing (261)
MASH (64)
Medical device (8394)
Medtech (8397)
Mergers & acquisitions (12652)
Metabolic disorders (596)
Multiple sclerosis (67)
NASH (17)
Neurodegenerative disease (87)
Neuropsychiatric disorders (29)
Neuroscience (1707)
NextGen: Class of 2025 (5051)
Non-profit (3588)
Now hiring (26)
Obesity (308)
Opinion (249)
Ovarian cancer (72)
Pain (70)
Pancreatic cancer (72)
Parkinson's disease (144)
Partnered (16)
Patents (176)
Patient recruitment (103)
Peanut (42)
People (41056)
Pharmaceutical (52)
Pharmacy benefit managers (11)
Phase I (17450)
Phase II (24054)
Phase III (17387)
Pipeline (1097)
Policy (139)
Postmarket research (1589)
Preclinical (7281)
Press Release (40)
Prostate cancer (90)
Psychedelics (36)
Radiopharmaceuticals (247)
Rare diseases (367)
Real estate (3620)
Recruiting (68)
Regulatory (16580)
Reports (28)
Research institute (1907)
Resumes & cover letters (404)
Rett syndrome (5)
RNA editing (5)
RSV (30)
Schizophrenia (69)
Series A (115)
Series B (74)
Service/supplier (3)
Sickle cell disease (54)
Special edition (15)
Spinal muscular atrophy (135)
Sponsored (25)
Startups (2808)
State (2)
Stomach cancer (7)
Supply chain (51)
Tariffs (40)
The Weekly (52)
Vaccines (587)
Venture capitalists (39)
Weight loss (202)
Women's health (24)
Worklife (20)
Date
Today (125)
Last 7 days (758)
Last 30 days (2123)
Last 365 days (27140)
2025 (8842)
2024 (29126)
2023 (32768)
2022 (41110)
2021 (44524)
2020 (42168)
2019 (35157)
2018 (26631)
2017 (24190)
2016 (22330)
2015 (26145)
2014 (19023)
2013 (14511)
2012 (15363)
2011 (16044)
2010 (14198)
Location
Africa (709)
Alabama (51)
Alaska (7)
Arizona (115)
Arkansas (9)
Asia (29145)
Australia (5058)
California (4970)
Canada (1670)
China (451)
Colorado (204)
Connecticut (217)
Delaware (136)
Europe (62488)
Florida (709)
Georgia (168)
Idaho (34)
Illinois (415)
India (20)
Indiana (198)
Iowa (4)
Japan (119)
Kansas (80)
Kentucky (16)
Louisiana (10)
Maine (46)
Maryland (702)
Massachusetts (3857)
Michigan (174)
Minnesota (261)
Mississippi (2)
Missouri (53)
Montana (23)
Nebraska (13)
Nevada (44)
New Hampshire (54)
New Jersey (1461)
New Mexico (19)
New York (1438)
North Carolina (740)
North Dakota (6)
Northern California (2150)
Ohio (164)
Oklahoma (10)
Oregon (28)
Pennsylvania (1064)
Puerto Rico (12)
Rhode Island (22)
South America (921)
South Carolina (19)
Southern California (1922)
Tennessee (61)
Texas (707)
United States (18531)
Utah (103)
Virginia (128)
Washington D.C. (50)
Washington State (487)
West Virginia (1)
Wisconsin (35)
475,732 Results for "go therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Bankruptcy
Bluebird’s Go-Private Deal Highlights Fraught Life Preserver for Struggling Biotechs
Facing declining valuations and funding challenges, public biotechs like bluebird bio are going private to restructure, reduce regulatory burdens and refocus on long-term growth.
March 12, 2025
·
6 min read
·
Ana Mulero
Layoffs
Spark Therapeutics Cuts 298 Employees as Part of Reorganization
Roche’s reorganization of Spark Therapeutics is coming more into focus, with nearly 300 employees being let go by the end of this year. Spark also trimmed its staff in 2024.
April 4, 2025
·
1 min read
·
Angela Gabriel
Manufacturing
With Pharma Throwing Billions At US Manufacturing, Where Is The Cash Going?
Major pharmaceutical companies are committing billions to US manufacturing in an effort to avoid steep tariffs threatened by President Donald Trump.
April 29, 2025
·
2 min read
·
Annalee Armstrong
Tariffs
China Still Go-To Source for New Drugs Despite Tariff Minefield
Policy uncertainties are impacting biopharma dealmaking from continent to continent, with companies being asked to walk a tightrope on their relations with China.
April 30, 2025
·
10 min read
·
Annalee Armstrong
Mergers & acquisitions
Novo Holdings Gets FTC’s Go-Ahead for Contentious $16.5B Catalent Acquisition
Now that they’ve received the go-signal from both U.S. and EU anti-trust regulators, Novo Holdings and Catalent expect to wrap up their deal in the coming days.
December 16, 2024
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Bluebird Draws Another Suitor Amid Plans To Go Private
Ayrmid’s offer is 50% higher than bluebird’s previously announced deal with Carlyle and SK Capital Partners.
March 31, 2025
·
2 min read
·
Tristan Manalac
Layoffs
Organon Lets Go of 93 Employees in New Jersey in Continuing Workforce Cuts
Organon’s workforce cuts come several months after the company’s loss of exclusivity to its second-largest product, Atozet.
April 1, 2025
·
2 min read
·
Angela Gabriel
Press Releases
Cycle Pharmaceuticals Launches Cycle Vita PKU™, an AI-Powered Smartphone App for On-The-Go Management of Phenylketonuria (PKU)
April 22, 2025
·
2 min read
Mergers & acquisitions
Bluebird, Facing Cash Crunch, To Go Private In Deal Valued at $30M
The proposed acquisition by global investment firms Carlyle and SK Capital Partners could net shareholders $3 per share plus potential CVR dollars and provide bluebird bio with primary capital to expand the commercial reach of its gene therapies.
February 21, 2025
·
3 min read
·
Heather McKenzie
Editorial
FDA Weathers Bait-and-Switch Storm as Staff and Sites Come and Go
Marty Makary, likely FDA commissioner under President Trump, appeared before Congress this week as the agency he’s set to lead continues to be rocked by sweeping changes and about-faces.
March 7, 2025
·
3 min read
·
Jef Akst
1 of 47,574
Next
